Overview

Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients

Status:
NOT_YET_RECRUITING

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant recipients with active CMV infection.

Phase:

PHASE4

Details

Lead Sponsor:

University Health Network, Toronto

Treatments:

Ganciclovir
letermovir
Valganciclovir